Cyclizine

CHEMBL648 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
266.4 g/mol
LogP
3.6
Phase
4

An antihistamine with antiemetic and anticholinergic properties used to prevent and treat nausea, vomiting, and motion sickness. It acts centrally in the vomiting center of the brain and is used perioperatively and for vertigo.

Berat Molekul

266,4000 g/mol

LogP

3,60

TPSA

6,50 Ų

Lipinski RO5

Lulus

Area Terapeutik

Mekanisme Kerja

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CN1CCN(C(c2ccccc2)c2ccccc2)CC1

InChI

InChI=1S/C18H22N2/c1-19-12-14-20(15-13-19)18(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18H,12-15H2,1H3

Molecular Formula

C18H22N2

HBD / HBA

- / 2

Ikatan yang Dapat Dirotasi

3

Atom Berat

20

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

An antihistamine with antiemetic and anticholinergic properties used to prevent and treat nausea, vomiting, and motion sickness. It acts centrally in the vomiting center of the brain and is used perioperatively and for vertigo.

Competitively blocks histamine H1 receptors on effector cells, preventing histamine-mediated vasodilation, increased vascular permeability, bronchoconstriction, and pruritus. First-generation agents also cross the blood-brain barrier, causing sedation.

Yes, Cyclizine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL648. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6726. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.